Alton Johnson is an industry leader and expert in pharmaceutical development, manufacturing, technology and business solutions. In his current consulting role, he develops strategies and solutions for clients in the areas of new product development, manufacturing, digital transformation, pharmaceutical technology, business development and compliance.
Stacey Bruzzese welcomes Alton Johnson to the show to discuss companies adopting appropriate technologies and the Internet of Things.
The topic of continuous manufacturing has drawn considerable interest across all modalities of pharmaceutical manufacturing.
Register today for the May 7th JLABS Webinar: 4 defining steps that could unlock your life science technology’s commercialization potential.
2020 ISPE Annual Meeting & Expo
1 – 4 Nov, Philadelphia Convention Center
Exhibitor: NGT BioPharma Booth # 712
2020 ISPE Facilities of the Future Conference
Training 28 – 29 Jan | Conference 30 – 31 Jan 2020, San Francisco
Presenter: Michael O’Brien – Presentation title: Transformational Biopharmaceutical Manufacturing and Supply Paradigm
On average, developing a new drug takes 12 years and costs $2.6 billion, with 9 out of 10 drugs entering clinical trials failing to enter the market 1. While digital technology and big data have led to paradigm shifts in other sectors (think Netflix, Uber, and Amazon), the biopharmaceutical industry has been considered a laggard on the digital integration front.
When contemplating new biopharmaceutical development and manufacturing facility construction, there are three commonly pursued industry options, Conventional, Modular, and Podular. Prior to embarking on a capital-intensive building project, it should be considered whether one of these three is a preferred approach. There is credible evidence to suggest that offsite prefabrication of a facility shell/utilities core and its modular equipment platform…
Approximately 20 to 25 participants representing pharma, biotech, academia, and government will come together in July to help define the future of AI in pharmaceutical R&D towards advancing health care in the United States. The specific focus will be to elucidate the opportunities and challenges for AI in drug discovery and development, with a broad view to the scientific, economic, ethical, legal and social aspects …
